KRIBIOLISA™ Risankizumab (SKYRIZI) ELISA

SKU: KBI1593 Category:

₹58,000.00

Enzyme Immunoassay for the estimation of Risankizumab in serum and plasma.

About the kit:
– Uses anti-idiotypic monoclonal antibodies which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%


The below Kit Insert is subject to change with the new lot of kits.

Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19
subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Risankizumab was approved by
the U.S. FDA for treatment of moderate-to-severe plaque psoriasis in April 2019, and in vitro, has been more
potent in inhibiting IL-23 signalling than other drugs performing in the same IL-23 complex.

Intended Use:
For Estimation of Risankizumab (SKYRIZI) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.

If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Species

Human
Biomarker Estimation

measures free drug
Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 2000 ng/ml
Detection Method

Colorimetric
Specificity

80% – 120% to Risankizumab
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring
Entez Gene ID

655066-01 Human
Alternate Names / Synonyms

Risankizumab, risankizumab-rzaa
Alternate Drug Brand Names

Skyrizi 150 Mg Dose Pack
Drug Bank Accession Number

DB14762
ELISA Type

Direct Sandwich Assay
Storage Temperature

Store the unopened product at 2-8 Deg C. Do not use past expiration date.
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products